NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
0
DON'T BUY
Just doesn't seem to be up to right itself. Spinning off a lot of cash but its size limits it from growing.
DON'T BUY
Getting killed by generics. They get sued when they hurt people. Government won't stand up for them when generics can provide health care at a fraction of the price. Prefer TEVA-O
DON'T BUY
Has been a difficult stock. Could improve from here however there will be other opportunities in this space you could get more juice from.
PAST TOP PICK
(A Top Pick April 10/08. Down 27.8%.) Paired with Teva (TEVA-Q) as his generic company. Down a little because of their intention to purchase Wyath. Cut their dividend but still gives a healthy yield. Good defensive place.
BUY
Made a good acquisition of Wyeth. Have created value in previous acquisitions. Cut the dividend while making the deal so the stock price fell. This made a lot of sense. The big issue is whether this will fill a hole in their product line. Reasonable dividend and very good balance sheet.
DON'T BUY
A former glory growth stock. A lot of healthcare products and there is the issue of aging in America but that is offset by many of their expensive premier drugs going generic. Just cut their dividends. Would prefer other pharmaceutical stocks.
PAST TOP PICK
(A Top Pick Feb 27/08. Down 40%.)
DON'T BUY
Cut the dividend in order to preserve cash to make acquisitions even though their balance sheets is fortress like. Lipitor is coming off patent in a couple of years. Stock has been very disappointing. A "show me" stock.
HOLD
(Market Call Minute.) Just completing an acquisition.
HOLD
At this price it is probably near a low. Made a big acquisition that is scaring everybody. Can't see a lot of downside from here.
SELL
Made a huge bet with their acquisition of Wyeth and the patents are running off. If it doesn't work out they are going to have some very difficult times.
TOP PICK
(A Top Pick Jan 7/08. Down 28,2%.) Likes it for its valuation and its recent acquisition of Wyeth, which gets them into biotechnology and vaccines. Cheap on an earnings basis. Over 4% dividend. In a recession, drug stocks do relatively well. Stock has been oversold.
BUY
Currently, pharmaceutical stocks are outperforming the market. A good place to hide and to make some money. Yield of 7.2%. Lots of cash.
TOP PICK
His model price is $24.87, a 50% upside. $24 billion in cash.
SELL
Get Out! Sell. Not a fan of pharmaceuticals. Feels innovations will be in biotechnology not pharmaceuticals.
Showing 496 to 510 of 894 entries